4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of “Moderate Buy” by Analysts

by · The Markets Daily

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $28.5556.

A number of equities research analysts have weighed in on FDMT shares. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target for the company in a report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. The Goldman Sachs Group reissued a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th.

Get Our Latest Stock Report on FDMT

4D Molecular Therapeutics Stock Up 6.7%

FDMT opened at $14.68 on Friday. 4D Molecular Therapeutics has a one year low of $6.47 and a one year high of $16.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The stock’s fifty day moving average is $12.73 and its 200-day moving average is $10.81. The company has a market capitalization of $810.92 million, a PE ratio of -5.58 and a beta of 2.74.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. On average, equities analysts predict that 4D Molecular Therapeutics will post -4.07 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction on Monday, September 14th. The stock was sold at an average price of $13.90, for a total value of $810,828.70. Following the transaction, the insider directly owned 767,486 shares in the company, valued at $10,668,055.40. The trade was a 7.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider directly owned 8,617 shares in the company, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 257,491 shares of company stock valued at $3,039,990 in the last quarter. Insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently bought and sold shares of FDMT. Persistent Asset Partners Ltd acquired a new position in shares of 4D Molecular Therapeutics in the second quarter worth about $1,936,000. Deutsche Bank AG acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at approximately $9,456,000. Dimensional Fund Advisors LP lifted its position in shares of 4D Molecular Therapeutics by 77.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock valued at $4,863,000 after acquiring an additional 227,982 shares in the last quarter. Exome Asset Management LLC acquired a new position in 4D Molecular Therapeutics in the 1st quarter worth approximately $1,216,000. Finally, Perigon Wealth Management LLC purchased a new position in 4D Molecular Therapeutics during the 2nd quarter worth approximately $1,944,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.

Further Reading